title: HCT survival in ADA-SCID: what's the buzz?
abstract: In this issue of Blood, Hassan et al have turned the spotlight on hematopoietic stem cell transplantation (HCT) of adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). They opened up the curtain of beliefs on this therapy that enables facts to be separated from fiction.
authors.affiliation: Baylor College of Medicine, USA.
authors.forename: Sanny K
authors.initials: SK
authors.lastname: Chan
authors.forename: William T
authors.initials: WT
authors.lastname: Shearer
mesh_terms: D000243:Adenosine Deaminase / Q000172:deficiency; D000361:Agammaglobulinemia / Q000188:drug therapy*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D016511:Severe Combined Immunodeficiency / Q000188:drug therapy*; D019172:Transplantation Conditioning
chemical_list: D000243:Adenosine Deaminase